⚡ Quick Start — If You Read Nothing Else

The 7 most important things to know right now.

No treatment without testing. Every patient with advanced non-squamous NSCLC must have comprehensive molecular profiling (biomarker testing) completed before starting systemic therapy. This single test can completely change your treatment plan — from chemotherapy to a targeted pill with fewer side effects and better outcomes. Starting immunotherapy before knowing your mutation status can reduce the effectiveness of targeted treatments later.
Biomarker testing identifies actionable targets in the majority of patients. Next-generation sequencing (NGS) can now detect treatable mutations in roughly 60–70% of adenocarcinoma cases. Key targets include EGFR, ALK, ROS1, KRAS G12C, BRAF V600E, MET exon 14, RET, NTRK, and HER2. If your tumor has one of these, you likely qualify for targeted oral therapy — often more effective and less toxic than chemotherapy.
Targeted therapy has transformed survival. Patients with EGFR mutations on osimertinib have median overall survival exceeding 38 months in advanced disease. The MARIPOSA trial showed amivantamab plus lazertinib further improves outcomes over osimertinib alone. ALK-positive patients on lorlatinib have 5-year progression-free survival rates exceeding 60%. These are oral pills, usually taken at home.
Immunotherapy can produce durable, long-lasting responses. For patients without driver mutations, immune checkpoint inhibitors (pembrolizumab, nivolumab, atezolizumab, durvalumab) can lead to responses lasting years in some patients. The PACIFIC regimen for stage III disease shows 5-year overall survival of 43% vs 33% without consolidation immunotherapy.
Perioperative immunotherapy is changing early-stage treatment. For surgically resectable NSCLC, giving immunotherapy before surgery (neoadjuvant) and/or after (adjuvant) dramatically improves cure rates. CheckMate 816, KEYNOTE-671, and AEGEAN have made this a new standard of care. If you are having surgery, ask about perioperative immunotherapy.
Early palliative care improves both quality of life and survival. Palliative care is NOT the same as hospice or giving up. A landmark study showed that patients who started palliative care at diagnosis lived longer (median 11.6 vs 8.9 months) and had better quality of life. Ask for a palliative care referral early — it works alongside your cancer treatment.
Screening saves lives. Low-dose CT screening for high-risk individuals (age 50–80, 20+ pack-year smoking history) detects lung cancer early when 5-year survival exceeds 80%. Fewer than 1 in 5 eligible Americans are being screened. In Utah, radon exposure is an additional risk factor — 1 in 3 Utah homes has dangerous radon levels.

▼ Collapse

Understanding Lung Cancer (NSCLC): A Revolution in Personalized Treatment

Non-small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancers and is the leading cause of cancer death worldwide, with roughly 1.8 million deaths per year globally. In the United States, an estimated 238,000 new cases are diagnosed annually. But the treatment landscape has been transformed over the past decade, and the prognosis for many patients is dramatically better than it was just a few years ago.

Why this is a hopeful moment. NSCLC treatment has entered a new era of personalized medicine. Molecular profiling now identifies treatable targets in the majority of adenocarcinoma patients. Targeted oral therapies produce responses lasting years. Immunotherapy can achieve durable remissions. Perioperative strategies are improving cure rates for early-stage disease. Five-year survival for advanced NSCLC has more than doubled over the past decade. While lung cancer remains a serious diagnosis, the pace of progress is extraordinary — new agents, combinations, and biomarkers are emerging from clinical trials every year.

This guide covers all major types of non-small cell lung cancer:

Adenocarcinoma — The most common type (~40% of NSCLC), often found in outer areas of the lung. Most common in never-smokers and younger patients. Most likely to harbor actionable driver mutations (EGFR, ALK, ROS1, KRAS G12C).

Squamous cell carcinoma — About 25–30% of NSCLC, strongly associated with smoking, typically arises in central airways. Less likely to have targetable mutations, but PD-L1 expression is common, making immunotherapy effective.

Large cell carcinoma — Less common (~5–10%), can occur anywhere in the lung, tends to grow and spread quickly. Increasingly classified by molecular features rather than histology alone.

Other subtypes — Adenosquamous, sarcomatoid, and other rare histologies are treated based on molecular profiling and the dominant component.

Lung cancer stage tells your doctors how far the cancer has spread. It is determined using the TNM system (T = tumor size and location, N = lymph node involvement, M = metastasis to distant organs) per the IASLC 9th Edition Staging Manual:

Stage I (IA1–IB) — Cancer is small and confined to the lung. Five-year survival exceeds 80% with surgery alone. Many patients are cured.
Stage II (IIA–IIB) — Cancer may be larger or has spread to nearby lymph nodes. Surgery plus adjuvant therapy (chemotherapy, immunotherapy, or targeted therapy) is standard. Five-year survival: 50–60%.
Stage III (IIIA–IIIC) — Cancer has spread to mediastinal lymph nodes or nearby structures. Treatment depends on whether surgery is feasible. For unresectable stage III, concurrent chemoradiation followed by consolidation durvalumab (PACIFIC regimen) is standard. Five-year survival: 20–40%.
Stage IV (IVA–IVB) — Cancer has spread to distant sites (other lung, bones, brain, liver, adrenals). Treatment is systemic (targeted therapy, immunotherapy, chemotherapy) and focused on controlling the disease and maintaining quality of life. Survival varies enormously depending on molecular subtype — from median 6–8 months for some to 3–5+ years for others with targeted therapy.

Key point: Stage alone does not determine your prognosis. Your molecular profile, performance status, and response to treatment matter enormously. Ask your doctor about all the factors that apply to you.

Smoking — The #1 risk factor, accounting for ~80% of lung cancer deaths. Quitting at ANY point — even after diagnosis — improves treatment outcomes, reduces toxicity, and extends survival. This is evidence-based, not just good advice.
Radon exposure — The #2 cause of lung cancer and the #1 cause in never-smokers. Radon is a colorless, odorless gas that seeps from soil into buildings. In Utah, about 1 in 3 homes has radon levels above the EPA action level (4 pCi/L). Test your home — kits are available at hardware stores or through the Utah Department of Environmental Quality.
Secondhand smoke, occupational exposures — Asbestos, diesel exhaust, certain chemicals. Air pollution is an increasingly recognized risk factor worldwide.
Never-smokers get lung cancer too — About 10–15% of lung cancer occurs in people who have never smoked. In East Asian populations, EGFR-mutant adenocarcinoma in never-smokers is particularly common (~50% of cases). Never-smokers should not assume they are immune.
Screening — Annual low-dose CT (LDCT) screening for ages 50–80 with 20+ pack-year history who currently smoke or quit within the past 15 years. The NLST and NELSON trials showed 20–26% reduction in lung cancer mortality. In the US, roughly 14.5 million people are eligible but fewer than 1 in 5 are getting screened.

What type and stage of lung cancer do I have?
Has comprehensive molecular profiling (NGS) been ordered, and when will results be available?
Am I a candidate for surgery? If not, why not?
Should I be seen by a multidisciplinary team (thoracic surgeon, medical oncologist, radiation oncologist)?
What is the goal of my treatment — cure, long-term control, or symptom relief?
How will we decide on my treatment plan once the biomarker results come back?

Important. This guide is educational and does not replace care from a qualified thoracic oncology team. It cannot diagnose anyone or recommend a specific treatment. Every treatment decision should be made with clinicians who know your full medical history and have reviewed your molecular profiling results.

Diagnosis & Biomarker Testing: The Foundation of Personalized Treatment

Critical message: No treatment without testing. If you have advanced non-squamous NSCLC, insist that comprehensive molecular profiling (broad NGS panel) is completed before starting any systemic therapy. This is the single most important step in your cancer care — it determines whether you receive a targeted oral therapy (often more effective, fewer side effects) or standard chemotherapy/immunotherapy. Starting immunotherapy before knowing your mutation status can be harmful if you later turn out to have an EGFR or ALK mutation.

What is biomarker testing?

Biomarker testing (also called molecular profiling, genomic testing, or mutation testing) analyzes your tumor's DNA and RNA to find specific genetic changes that drive the cancer's growth. When a “driver mutation” is found, there may be a targeted drug designed specifically for it. Think of it as finding the cancer’s unique weakness.

Biomarker	Frequency in NSCLC	Targeted treatment available?	What to know
EGFR mutations	~15% (Western), ~50% (East Asian)	Yes — osimertinib, amivantamab+lazertinib, others	Most common actionable target. Multiple lines of therapy available. MARIPOSA trial established amivantamab+lazertinib as first-line option.
ALK rearrangements	~5%	Yes — alectinib, lorlatinib, brigatinib	More common in younger patients and never-smokers. Lorlatinib (CROWN trial) shows 5-year PFS >60%.
KRAS G12C	~13%	Yes — sotorasib, adagrasib	Once considered “undruggable.” Next-generation inhibitors (divarasib, olomorasib) in advanced trials with improved results. Olomorasib combined with pembrolizumab has shown high response rates in early-phase trials and is moving into larger studies.
ROS1 fusions	~1–2%	Yes — entrectinib, crizotinib, repotrectinib	Highly sensitive to targeted therapy. Repotrectinib effective against resistance mutations.
BRAF V600E	~2%	Yes — dabrafenib + trametinib	Same drugs used in melanoma. High response rates.
MET exon 14 skipping	~3%	Yes — capmatinib, tepotinib	More common in older patients and sarcomatoid histology.
RET fusions	~1–2%	Yes — selpercatinib, pralsetinib	LIBRETTO-431: selpercatinib superior to chemotherapy+IO in first-line.
NTRK fusions	<1%	Yes — larotrectinib, entrectinib	Tumor-agnostic approval — works regardless of where the cancer started.
HER2 mutations	~2–3%	Yes — zongertinib (Hernexeos, oral) or trastuzumab deruxtecan (T-DXd)	Zongertinib (oral HER2 TKI) FDA-approved 2025, expanded to first-line Feb 2026 (Beamion LUNG-1, ORR 76% first-line). T-DXd is an ADC infusion (DESTINY-Lung02, ORR ~49%).
PD-L1 expression	Variable (tested in all patients)	Predicts response to immunotherapy	High PD-L1 (≥50%) → may receive IO monotherapy. Low/negative → IO+chemo. NOT a treatment target itself but guides therapy selection.

Tissue biopsy with NGS (next-generation sequencing) — The gold standard. A broad panel testing all major targets simultaneously from a tumor sample. Takes 1–3 weeks. Requires adequate tissue — discuss tissue stewardship with your pathologist.
Liquid biopsy (ctDNA / circulating tumor DNA) — A blood draw that detects tumor DNA fragments circulating in your blood. Faster turnaround (often 7–10 days). Can be done when tissue is insufficient or while waiting for tissue results. Complements tissue testing but does not fully replace it (may miss some alterations).
PD-L1 immunohistochemistry (IHC) — A stain done on tumor tissue to measure PD-L1 protein expression. Guides immunotherapy decisions. Should be done for all patients regardless of mutation status.
RNA-based testing — Important for detecting fusions (ALK, ROS1, RET, NTRK) that may be missed by DNA-only panels. Ensure your NGS panel includes RNA sequencing.

Practical tip: If you are being told to start chemotherapy or immunotherapy before biomarker results are back, ask your doctor if waiting a few more days is safe. In most cases, a short delay to get results is far better than starting the wrong treatment. The only exception is rapidly declining patients who need urgent treatment.

About 30–40% of patients will have no actionable driver mutation detected. This does NOT mean biomarker testing was wasted. It means:

Your treatment will be guided by PD-L1 expression and other clinical factors
Immunotherapy (alone or with chemotherapy) is typically the first-line treatment
Immunotherapy can produce excellent, durable responses in many patients without driver mutations
Your doctor may recommend re-testing at progression to look for emerging targets
New targets and treatments are being discovered continuously — what is negative today may become actionable in the future

Has a broad NGS panel (not just single-gene tests) been ordered on my tumor?
Is the panel testing DNA and RNA (RNA is needed to detect fusions)?
Should I also have a liquid biopsy while we wait for tissue results?
What is my PD-L1 score, and what does it mean for my treatment options?
If I have an actionable mutation, what targeted therapy is recommended and why?
How long until we get the full molecular profiling results?
Can we safely wait for results before starting treatment?
Will my case be discussed at a molecular tumor board?

Caregiver note. Biomarker results can feel overwhelming. Ask the team to explain what the results mean in plain language. Keep a copy of the molecular profiling report — you may need it for second opinions, clinical trial screening, or if you change treatment centers. The key question is: “Does my loved one have an actionable mutation, and if so, which targeted therapy is recommended?”

Treatment Options: How Your Cancer Is Treated Depends on Stage and Biomarkers

There is no single “best treatment” for NSCLC. The right approach depends on your cancer’s stage, molecular profile, overall health, and personal preferences. Treatment typically falls into these major categories:

Surgery

Surgery offers the best chance of cure for early-stage NSCLC (stages I–IIIA in select cases).

Lobectomy — Removal of the entire lobe containing the tumor. Standard for most patients with adequate lung function.
Sublobar resection (segmentectomy or wedge) — Removes a smaller portion of the lung. The JCOG0802 and CALGB 140503 trials demonstrated that segmentectomy is non-inferior to lobectomy for tumors ≤2 cm, with better preserved lung function.
Minimally invasive approaches (VATS, robotic) — Smaller incisions, less pain, faster recovery. Now used in the majority of early-stage surgeries at experienced centers.
Mediastinal lymph node assessment — Critical for accurate staging. Done during surgery or beforehand with EBUS (endobronchial ultrasound).

Recovery: Hospital stay typically 3–5 days for minimally invasive surgery. Most patients return to normal activities within 4–8 weeks. Breathing may be slightly reduced but usually compensated well.

Perioperative therapy (before and/or after surgery)

One of the biggest advances in NSCLC in recent years is the integration of immunotherapy with surgery. This is called “perioperative” therapy and has been shown to significantly improve cure rates:

Neoadjuvant chemoimmunotherapy (before surgery): CheckMate 816 showed nivolumab + chemotherapy before surgery produced a 24% pathologic complete response (pCR) rate — meaning no cancer found in the surgical specimen. Event-free survival (EFS) was significantly improved, and OS benefit has now been confirmed.
Perioperative IO (before AND after surgery): KEYNOTE-671 (pembrolizumab), AEGEAN (durvalumab), and CheckMate 77T (nivolumab) all demonstrated improved EFS (~60–65% event-free at 2 years) with immunotherapy given both before and after surgery.
Adjuvant targeted therapy: ADAURA showed 3 years of adjuvant osimertinib after surgery for EGFR-mutant stage IB–IIIA NSCLC dramatically improved disease-free survival (HR 0.17 for stage II–IIIA). This is now standard of care for resected EGFR-mutant NSCLC.

Key takeaway: If you are having surgery for NSCLC, ask your oncologist about perioperative immunotherapy or targeted therapy. Treatment before and/or after surgery is rapidly becoming standard for stages IB–IIIA.

Radiation therapy

SBRT/SABR (stereotactic body radiation therapy) — Highly focused radiation delivered in 3–5 treatments for early-stage patients who cannot have surgery. Cure rates approach surgery for small tumors. Outpatient treatment with minimal side effects.
Concurrent chemoradiation — For unresectable stage III disease, chemotherapy and radiation are given simultaneously, followed by up to 12 months of consolidation durvalumab (PACIFIC regimen). PACIFIC demonstrated 5-year overall survival of 42.9% vs 33.4% and 5-year PFS of 33.1% vs 19.0%.
Stereotactic radiosurgery (SRS) for brain metastases — Preferred over whole-brain radiation (WBRT) for limited brain metastases. Better cognitive preservation. Can be repeated if new lesions develop.
Palliative radiation — For symptom relief: pain from bone metastases, airway obstruction, brain metastases causing symptoms.

Targeted therapy (for patients with actionable mutations)

Targeted therapies are drugs designed to attack the specific molecular alteration driving your cancer. They are usually oral pills taken daily at home.

EGFR-mutant NSCLC (the most common actionable mutation):

Osimertinib (Tagrisso) — Third-generation EGFR TKI. Standard first-line for common EGFR mutations (exon 19 deletion, L858R). FLAURA trial: median OS 38.6 months. Excellent brain penetration. Generally well tolerated (diarrhea, rash, dry skin are common but manageable).
Amivantamab + lazertinib — MARIPOSA trial showed this combination provides superior PFS over osimertinib alone (HR 0.70) and improved OS (HR 0.75). Now a first-line option, especially for patients at higher risk of early progression. Amivantamab is an IV infusion; lazertinib is an oral pill.
Exon 20 insertions — Historically hard to treat. Amivantamab plus chemotherapy is an FDA-approved first-line option (PAPILLON trial: response rate ~73%). Sunvozertinib (Zegfrovy) is approved for patients whose cancer has already been treated with chemotherapy (response rate ~46% in the WU-KONG1B trial); its use as a first-line treatment is still being studied (the WU-KONG28 trial reported a ~59% response rate).

ALK-positive NSCLC:

Alectinib — Standard first-line (ALEX trial). Well tolerated with excellent CNS activity.
Lorlatinib — Third-generation ALK inhibitor with remarkable durability. CROWN trial: 5-year PFS >60%. Best CNS penetration. Used first-line or after prior ALK TKI failure.

KRAS G12C:

Sotorasib and adagrasib — First-generation KRAS G12C inhibitors. ORR ~30–40% in second-line.
Next-generation agents — Divarasib showed ORR 55.6% and median PFS 13.8 months. Olomorasib combined with pembrolizumab showed high response rates in early-phase trials. These represent significant improvements over first-generation agents.

HER2 (ERBB2)-mutant NSCLC:

Zongertinib (Hernexeos) — The first oral pill for HER2-mutant NSCLC, a HER2-selective tyrosine kinase inhibitor. The FDA granted accelerated approval in August 2025 (after prior therapy) and expanded it to first-line/treatment-naive use in February 2026. In the Beamion LUNG-1 trial, 76% of previously untreated patients had their tumors shrink. Taken once daily.
Trastuzumab deruxtecan (T-DXd, Enhertu) — An antibody-drug conjugate (IV infusion, not a pill) with ORR ~49% in previously treated patients (DESTINY-Lung02). An important option, particularly after progression.

Other targets: ROS1 fusions (entrectinib, repotrectinib), BRAF V600E (dabrafenib + trametinib), MET exon 14 (capmatinib, tepotinib), RET fusions (selpercatinib), NTRK fusions (larotrectinib, entrectinib). Each has specific FDA-approved therapies.

Immunotherapy (for patients without driver mutations)

Immune checkpoint inhibitors “release the brakes” on your immune system so it can recognize and attack cancer cells. These are IV infusions given every 3–6 weeks.

PD-L1 ≥50% (high expression): Pembrolizumab monotherapy (KEYNOTE-024) or IO+chemotherapy. IO alone avoids chemotherapy side effects but IO+chemo may have slightly higher response rates.
PD-L1 1–49%: IO+chemotherapy combination is standard (KEYNOTE-189 for non-squamous, KEYNOTE-407 for squamous). Alternatives include nivolumab+ipilimumab+2 cycles chemo (CheckMate 9LA).
PD-L1 <1% (negative): IO+chemotherapy, or nivolumab+ipilimumab+chemo. IO alone is not recommended.

Important: Immunotherapy is generally NOT recommended as first-line treatment for patients with EGFR, ALK, or other driver mutations — it has poor efficacy in these patients and can cause problematic side effects if targeted therapy is started afterward.

Side effects of immunotherapy are different from chemotherapy. The immune system can attack healthy organs (immune-related adverse events or irAEs). Report any new persistent symptom to your oncology team immediately — early intervention is critical. The most common irAEs include thyroid problems, skin rash, fatigue, colitis (diarrhea), and pneumonitis (lung inflammation).

Chemotherapy

While targeted therapy and immunotherapy have transformed NSCLC treatment, chemotherapy remains important:

Platinum doublets — Cisplatin or carboplatin paired with pemetrexed (non-squamous) or paclitaxel/gemcitabine (squamous). Often combined with immunotherapy in first-line treatment.
Neoadjuvant setting — Platinum chemotherapy combined with immunotherapy before surgery.
Later lines — Docetaxel (+/- ramucirumab), gemcitabine, or other agents after targeted therapy or immunotherapy progression.
Common side effects: Nausea (well controlled with modern antiemetics), fatigue, hair thinning or loss, low blood counts (risk of infection — neutropenic fever is an emergency). Side effects are generally manageable and temporary.

Antibody-drug conjugates (ADCs): a new class of treatment

ADCs are engineered molecules that combine an antibody (which finds the cancer cell) with a potent chemotherapy payload (which kills it). They deliver chemotherapy directly to cancer cells while sparing healthy tissue.

Trastuzumab deruxtecan (T-DXd, Enhertu) — For HER2-mutant NSCLC. ORR ~49% in previously treated patients.
Datopotamab deruxtecan (Dato-DXd, Datroway) — Targets TROP2. Received FDA accelerated approval in June 2025 for EGFR-mutated NSCLC that has progressed on prior osimertinib and platinum-based chemotherapy. Expanding the options for patients with limited remaining choices.
Telisotuzumab vedotin (Emrelis) — A MET-directed ADC that received FDA accelerated approval in May 2025 for adults with locally advanced or metastatic non-squamous NSCLC with high c-Met protein overexpression after prior systemic therapy (35% ORR in the LUMINOSITY trial).
Emerging ADCs — Patritumab deruxtecan (HER3-directed) and sacituzumab govitecan (TROP2) are in active clinical trials.

Key side effect to know: ADCs can cause interstitial lung disease (ILD) / pneumonitis. Any new cough, shortness of breath, or chest discomfort should be reported immediately. Early detection and management is critical.

Based on my stage and biomarkers, what is the recommended treatment plan?
What are the expected benefits and risks of this treatment?
Am I a candidate for surgery? If so, should I receive neoadjuvant therapy first?
If I have a driver mutation, which targeted therapy do you recommend and why?
How will we know if the treatment is working?
What side effects should I watch for, and when should I call urgently?
What happens if the first treatment stops working?
Are there clinical trials I should consider?
Should I get a second opinion at a major cancer center?

Caregiver note. Treatment for NSCLC can involve many moving parts: infusion schedules, oral medications, scans, lab work, and specialist appointments. Consider keeping a treatment binder or digital folder with: medication list and schedule, contact numbers for the oncology team, biomarker results, scan reports, and insurance prior authorization information (especially for targeted therapies, which can be expensive). Many cancer centers have patient navigators who can help coordinate care.

Advanced Disease, Resistance, and Clinical Trials

When treatment stops working: resistance and next steps

Cancer cells can develop resistance to targeted therapy and immunotherapy over time. This is not a failure — it is a biological reality. When progression occurs:

Re-biopsy (tissue and/or liquid biopsy) is critical at progression to identify the specific resistance mechanism. Different resistance mechanisms require different treatments.
EGFR resistance examples: T790M mutation (treated with osimertinib if on earlier TKI), C797S mutation, MET amplification (add MET inhibitor), small cell transformation (switch to platinum/etoposide).
ALK resistance: Different mutations respond to different next-generation ALK inhibitors. Lorlatinib covers the broadest range of resistance mutations.
Immunotherapy resistance: May benefit from different combinations, ADCs, or clinical trial approaches.

Key takeaway: Multiple lines of therapy are available for most NSCLC patients. When one treatment stops working, there are usually others to try. Re-testing at progression is essential.

Brain metastases

About 20–40% of NSCLC patients develop brain metastases. This is particularly common in ALK-positive and EGFR-mutant disease. Treatment options have improved dramatically:

Stereotactic radiosurgery (SRS) — Preferred for limited brain metastases (1–4 lesions). Preserves cognitive function better than whole-brain radiation. Can be repeated.
Targeted TKIs with CNS penetration — Osimertinib, lorlatinib, and alectinib all cross the blood-brain barrier effectively. Many patients with brain metastases can have CNS disease controlled by their oral targeted therapy alone, with SRS reserved for refractory lesions.
Leptomeningeal disease — Cancer in the fluid surrounding the brain and spinal cord. More difficult to treat but intrathecal therapy and CNS-penetrant agents are options.

All patients with advanced NSCLC should have a brain MRI at diagnosis and regular monitoring thereafter.

Oligometastatic disease

When cancer has spread to only 1–3 sites (oligometastatic disease), aggressive local treatment (surgery or SBRT) of all disease sites combined with systemic therapy can sometimes produce long-term disease control. This is an active area of research with several ongoing clinical trials. Discuss with your oncologist whether oligometastatic-directed therapy is appropriate for your situation.

Clinical trials

Clinical trials are the pathway through which every effective cancer treatment was discovered. They offer access to cutting-edge therapies that may not yet be available otherwise. In NSCLC, some of the most promising areas include:

Next-generation KRAS inhibitors — Divarasib (KRASCENDO-1 Phase 3 recruiting), olomorasib combinations
Novel ADCs — New targets (HER3, CEACAM5, MET), improved payloads
Personalized cancer vaccines — mRNA and neoantigen-based vaccines in the adjuvant setting
ctDNA-guided therapy (MRD-directed) — Using circulating tumor DNA to guide who needs treatment after surgery. ctDNA positivity precedes visible recurrence by a median of 88 days. NCT06198868 is actively recruiting.
Bispecific antibodies — Targeting multiple pathways to overcome or prevent resistance
Cell therapy — TIL therapy and adapted CAR-T approaches for solid tumors

How to find trials:

ClinicalTrials.gov — search “NSCLC” filtered by your biomarker, phase, and location
NCI Cancer Information Service — 1-800-4-CANCER for personalized trial matching
Your cancer center’s clinical trials office — HCI at the University of Utah and Intermountain Health both maintain active lung cancer trial portfolios
The LungMAP/S1400 master protocol and ALCHEMIST are cooperative group platforms matching patients to trials by biomarker

Landmark trials you can look up on ClinicalTrials.gov (these established today’s standard treatments): FLAURA (NCT02296125, osimertinib for EGFR); MARIPOSA (NCT04487080, amivantamab+lazertinib); CROWN (NCT03052608, lorlatinib for ALK); PAPILLON (NCT04538664, EGFR exon 20); PACIFIC (NCT02125461, durvalumab after chemoradiation); CheckMate-816 (NCT02998528, immunotherapy before surgery); and KEYNOTE-189 (NCT02578680, immunotherapy plus chemotherapy). Each NCT number is the trial’s unique identifier you can paste into ClinicalTrials.gov.

Important: Being in a clinical trial does not mean you are a “guinea pig.” You receive at least standard-of-care treatment, with the possibility of receiving something better. Trial participants are closely monitored with additional safety checks.

Combination strategies to overcome resistance — Adding MET inhibitors to EGFR TKIs, combining targeted therapy with immunotherapy for select populations
Amivantamab + lazertinib — An FDA-approved first-line option in the United States since August 2024 (MARIPOSA trial), and also approved in Japan (PMDA, March 2025) and Europe. It improves survival versus osimertinib alone but has more side effects, so the choice is individualized
Dato-DXd (Datroway) — FDA accelerated approval June 2025 for EGFR-mutated NSCLC after prior EGFR-targeted therapy and platinum chemotherapy
Sevabertinib (Hyrnuo) — an oral HER2-targeted pill; FDA accelerated approval November 2025 for previously-treated HER2-mutant NSCLC
Multiple new FDA approvals in NSCLC in 2025–2026 — The field continues to evolve rapidly with new targeted therapies and ADCs
Perioperative strategies for EGFR-mutant disease — NeoADAURA exploring perioperative osimertinib for early-stage EGFR-mutant NSCLC

If my cancer progresses, will you do a re-biopsy (or liquid biopsy) to find the resistance mechanism?
What second-line and third-line treatments are available for my specific mutation type?
Am I eligible for any clinical trials right now?
Should I be seen at a comprehensive cancer center (like HCI) for a molecular tumor board review?
How are my brain metastases being monitored and managed?
Is my disease oligometastatic, and if so, should local therapy be considered?

Caregiver note. Treatment resistance can be emotionally devastating. Remind your loved one that progression on one therapy usually means pivoting to the next — not the end of options. Help them connect with a clinical trials navigator and consider seeking a second opinion at an NCI-designated cancer center if not already being treated at one. Caregivers may find this phase especially draining — seek support for yourself through organizations like CancerCare (1-800-813-HOPE).

Living Well & Survivorship

Palliative care: not just for end of life

A landmark study by Temel et al. (NEJM, 2010) showed that patients with advanced NSCLC who started palliative care at diagnosis lived longer (median 11.6 vs 8.9 months) and had significantly better quality of life than those who received standard oncology care alone.

Palliative care is NOT the same as hospice. It is specialist care focused on:

Pain management and symptom control
Breathing difficulties and fatigue
Emotional and psychological support
Advance care planning
Coordinating care between specialists
Helping with goals-of-care conversations

Palliative care works ALONGSIDE your cancer treatment, not instead of it. You can receive aggressive cancer-directed therapy and palliative care simultaneously. Ask for a palliative care referral at diagnosis.

Managing common side effects

EGFR TKI side effects (osimertinib, amivantamab+lazertinib):

Skin rash and acneiform eruption — moisturize regularly, sun protection, ask about prophylactic minocycline or doxycycline. Report severe rash promptly.
Diarrhea — loperamide (Imodium) is first-line treatment. Stay hydrated. Call if >4 loose stools/day or unable to drink.
Dry skin, paronychia (nail infections) — gentle skin care, avoid harsh soaps, see dermatology for severe nail issues.
Amivantamab-specific: infusion-related reactions (usually mild, pre-medicate), periorbital edema, VTE risk.

Immunotherapy irAEs:

Thyroid dysfunction — Common, usually manageable with thyroid hormone replacement. Regular monitoring.
Pneumonitis — New cough or shortness of breath needs urgent evaluation. This can be serious.
Colitis — Persistent diarrhea with cramping. May need steroids.
Hepatitis — Usually found on blood tests before symptoms. Regular lab monitoring.
Rule of thumb: ANY new persistent symptom on immunotherapy should be reported to your team. Early treatment of irAEs leads to better outcomes.

Chemotherapy:

Nausea — Modern antiemetics (ondansetron, dexamethasone, aprepitant) make this much more manageable than in past decades.
Fatigue — The most common complaint. Light exercise actually helps. Pace yourself.
Neutropenia (low white blood cells) — Fever during chemotherapy (≥100.4°F / 38°C) is an emergency — go to the ER immediately, do not wait until morning.

Nutrition and wellness

Maintain weight and muscle mass. Cancer-related weight loss (cachexia) is common in lung cancer. High-protein meals and snacks. Consider nutritional supplements (Ensure, Boost) if eating is difficult. Ask for a registered dietitian (RD) or certified specialist in oncology nutrition (CSO) referral.
Stay physically active. Exercise during cancer treatment is safe and beneficial. Even 15–20 minutes of walking most days improves fatigue, mood, and treatment tolerance. Formal exercise programs like the LIVESTRONG at the YMCA or HCI’s Wellness & Integrative Health program are excellent resources.
Smoking cessation is a treatment. Quitting smoking at any point — even after an advanced diagnosis — improves treatment efficacy, reduces surgical complications, and extends survival. Ask about cessation support: nicotine replacement, varenicline, counseling. The Utah Tobacco Quit Line: 1-800-QUIT-NOW.

Supplement safety warning. If you are taking any dietary supplements, herbal products, or over-the-counter remedies, tell your oncology team. Some supplements can interfere with cancer treatments. For example, turmeric/curcumin can inhibit CYP450 enzymes that metabolize many targeted therapies. Green tea (EGCG) can modulate drug metabolism. St. John’s Wort can dramatically reduce effectiveness of many cancer drugs. Studies show that many cancer patients use supplements but do not disclose this to their oncologists.

Emotional health and support

Lung cancer carries unique psychological burdens including stigma (the assumption that patients “caused” their disease by smoking), guilt, anxiety about treatment decisions, and fear of progression. Depression and anxiety are common and treatable.

Ask for a psycho-oncology or social work referral — these specialists understand the unique challenges of cancer diagnosis
Support groups (in-person and online) connect you with others going through similar experiences
The stigma around lung cancer is unjust — many patients are never-smokers, and even those who smoked deserve the same compassion and quality of care as anyone with cancer
Screen for depression and anxiety regularly — treatment improves both quality of life and cancer outcomes
Fertility and sexual health — If you are of reproductive age, ask about fertility preservation before starting treatment. Most cancer treatments (TKIs, immunotherapy, chemotherapy) can harm an unborn child. Discuss contraception, sexual health concerns, and family planning with your oncology team early in the process.

Survivorship

For patients who have completed curative-intent treatment (surgery +/- perioperative therapy, or definitive chemoradiation):

Surveillance imaging — CT scans every 6 months for the first 2–3 years, then annually. Brain MRI for those with higher risk histologies.
ctDNA monitoring (emerging) — Circulating tumor DNA testing can detect molecular recurrence a median of 88 days before it appears on imaging. While not yet standard of care, ask about ctDNA monitoring if available at your center.
Second primary cancers — Lung cancer survivors have an increased risk of second lung cancers and other malignancies. Continued screening is important.
Survivorship care plan — Ask for a written plan that includes your diagnosis, all treatments received, surveillance schedule, and late effects to monitor.

Can I have a palliative care referral now, alongside my cancer treatment?
What should I do about my skin rash / diarrhea / fatigue?
Am I safe to exercise during treatment? What kind and how much?
Can I see a dietitian to help maintain my weight during treatment?
Is this supplement I am taking safe with my cancer medication?
What is my surveillance schedule after completing treatment?
Is ctDNA monitoring available, and should I consider it?
Who should I talk to about the emotional impact of this diagnosis?

Caregiver note. Caregiver burnout is real, especially during long treatment courses that can span months to years. Prioritize your own health. Seek support through CancerCare (1-800-813-HOPE), the ACSM Cancer Exercise Trainer program, or local caregiver support groups at HCI or Intermountain. You cannot pour from an empty cup. Know when to ask for help — from family, friends, social workers, or respite care services.

Support & Resources

National resources

American Cancer Society (ACS) — 1-800-227-2345. Free lodging (Hope Lodge), transportation assistance, 24/7 information line.
Lung Cancer Research Foundation — Research funding, patient education, support groups.
American Lung Association — Lung cancer support, screening resources, lung health programs.
CancerCare — 1-800-813-HOPE. Free professional counseling, support groups, financial assistance for lung cancer patients.
National Cancer Institute (NCI) — 1-800-4-CANCER. Cancer information, clinical trial matching, research updates.
LUNGevity Foundation — Survivorship, clinical trial finder, biomarker testing education.
GO2 for Lung Cancer — Peer-to-peer support, helpline, tobacco cessation support, stigma reduction.
Patient Advocate Foundation — 1-800-532-5274. Insurance navigation, prior authorization appeals, copay assistance.

Financial assistance

Targeted therapies and immunotherapy can be expensive. Many resources exist to help:

Manufacturer patient assistance programs — Most pharmaceutical companies offer free or reduced-cost medications for eligible patients. Ask your oncology team’s social worker or pharmacist to help you apply.
Copay assistance foundations — HealthWell Foundation, Patient Access Network Foundation, CancerCare copay assistance.
Insurance navigation — Patient Advocate Foundation helps with prior authorization, appeals, and coverage disputes.
Social Security Disability — Lung cancer qualifies for expedited processing under the Compassionate Allowance program.

Utah & local resources

Huntsman Cancer Institute (HCI) at the University of Utah — NCI-designated Comprehensive Cancer Center. Thoracic oncology multidisciplinary clinic, molecular tumor board, lung cancer screening program, extensive clinical trials portfolio, HCI Wellness & Integrative Health. healthcare.utah.edu/huntsmancancerinstitute
Intermountain Health — Precision Genomics program with comprehensive molecular testing, thoracic surgery and radiation oncology across Utah locations, tumor board at Intermountain Medical Center (Murray). intermountainhealthcare.org
VA Salt Lake City Health Care System — Thoracic oncology, access to VA cooperative group clinical trials, high-volume lung cancer program (veteran smoking exposure). va.gov/salt-lake-city-health-care
Utah Department of Environmental Quality — Radon Program — Free or low-cost radon test kits, mitigation guidance. Utah is among the states with the highest radon levels, with about 1 in 3 homes above safe levels. Radon is the #1 cause of lung cancer in never-smokers. deq.utah.gov radon program
Utah Tobacco Quit Line — 1-800-QUIT-NOW (1-800-784-8669). Free coaching and nicotine replacement therapy for Utah residents.
Altitude considerations — Utah’s elevation (4,000–5,000 ft in the Wasatch Front) may affect recovery after lung surgery. Discuss supplemental oxygen needs and activity planning with your surgical team.

International resources

IASLC (International Association for the Study of Lung Cancer) — Global staging system, World Conference on Lung Cancer, international guidelines.
ESMO (European Society for Medical Oncology) — European guidelines, ESCAT molecular target classification.
Japan Lung Cancer Society (JLCS) — Japanese treatment guidelines, EGFR-focused research. Note: Drug approvals in Japan are granted by the PMDA (Pharmaceuticals and Medical Devices Agency), not JLCS.
CSCO (Chinese Society of Clinical Oncology) — Chinese guidelines, domestically developed agents (aumolertinib, furmonertinib, sunvozertinib, sintilimab, camrelizumab).
ClinicalTrials.gov — US and global trial registry.
EU Clinical Trials Register — European trial database.
jRCT (Japan Registry of Clinical Trials) — Japanese clinical trials.
ChiCTR (Chinese Clinical Trial Registry) — Chinese clinical trials.

Global context: NSCLC is the #1 cancer killer worldwide. However, outcomes vary dramatically based on access to molecular testing and targeted therapies. EGFR-mutant NSCLC is especially common in East Asia (~50% of adenocarcinomas) compared to Western populations (~15%). Many countries are still establishing comprehensive molecular testing programs. If you are receiving care in a resource-limited setting, advocate for molecular testing — it fundamentally changes treatment decisions.

Can I see a social worker to help with insurance, financial assistance, and emotional support?
Are there patient assistance programs for the specific drugs I am taking?
Can you connect me with a lung cancer support group?
Should I be seen at HCI, Intermountain, or another specialized center for any part of my care?
Should my family members be screened for lung cancer?
Should I test my home for radon?

You are not alone. A lung cancer diagnosis can feel isolating, especially given the stigma that unfairly surrounds this disease. But effective treatment options have never been more numerous, and the community of patients, caregivers, researchers, and advocates has never been stronger. Reach out, ask questions, and know that many people with NSCLC are living longer and better than ever before.

International Approaches: East-Asian NSCLC

Lung cancer biology is not the same everywhere. EGFR mutations — the single most important targetable driver in NSCLC — are found in roughly 40–50% of adenocarcinomas in East-Asian patients (especially never-smokers and women), compared with approximately 15% in Western populations. This difference fundamentally shapes testing strategies, treatment guidelines, and drug development across the globe.

Why this matters to you. Even if you are receiving care in the United States, understanding the international landscape is valuable. Some drugs approved and widely used in China or Japan may eventually receive FDA approval, become available through clinical trials, or inform your oncologist’s thinking about next steps — particularly if standard options have been exhausted. The NSCLC research ecosystem is genuinely global.

China-developed targeted therapies (NMPA-approved)

China has developed and approved (through its National Medical Products Administration, NMPA) a parallel class of targeted therapies not available in the US. These drugs are used by hundreds of millions of patients and are increasingly studied in international trials.

Icotinib (Conmana) — China’s first domestically developed EGFR-TKI. NMPA-approved in 2011. A 1st-generation inhibitor comparable to gefitinib, used in patients with EGFR exon 19 deletion or exon 21 L858R mutations.
Aumolertinib / almonertinib (Ameile) — A 3rd-generation EGFR-TKI. NMPA-approved in 2020 for T790M-positive NSCLC after prior EGFR-TKI failure; granted 1st-line approval in 2021 based on the AENEAS trial. Designed to cross the blood-brain barrier, relevant for patients with brain metastases.
Furmonertinib — A 3rd-generation EGFR-TKI. NMPA-approved in 2021 for T790M-positive disease; 1st-line approval in 2022 based on the FURLONG trial. Notably, furmonertinib has received FDA Breakthrough Therapy Designation for EGFR exon 20 insertion mutations — a historically difficult-to-treat subgroup — making it one of the first China-developed TKIs to gain this US regulatory recognition.

Ensartinib — An ALK inhibitor. NMPA-approved in 2020 for 2nd-line ALK-positive NSCLC and in 2022 for 1st-line use based on the eXalt3 trial, which showed non-inferiority to crizotinib with superior CNS activity.
Savolitinib — A highly selective MET inhibitor for patients with MET exon 14 skipping mutations. Studied in the SACHI trial. Addresses a molecular subgroup (~3–4% of NSCLC) with limited approved options globally.

China has developed and approved multiple immune checkpoint antibodies for NSCLC indications, expanding access to immunotherapy for its population:

Camrelizumab — PD-1 antibody. NMPA-approved for NSCLC. Studied in the CameL and CameL-sq trials for non-squamous and squamous NSCLC, respectively.
Sintilimab — PD-1 antibody. NMPA-approved for NSCLC. The ORIENT-11 and ORIENT-12 trials demonstrated benefit in combination with chemotherapy.
Tislelizumab — PD-1 antibody. NMPA-approved for NSCLC. The RATIONALE-303, -304, and -307 trials supported multiple-line approvals. Tislelizumab is also being evaluated globally by the FDA.
Sugemalimab — PD-L1 antibody. NMPA-approved for NSCLC. The GEMSTONE-302 trial demonstrated benefit in combination with chemotherapy for both squamous and non-squamous histologies.

These agents are generally well tolerated with immune-related adverse event profiles similar to pembrolizumab and nivolumab. They have collectively expanded immunotherapy access to millions of patients in China and are under evaluation in international studies.

Regional guidelines and global coordination

CSCO (Chinese Society of Clinical Oncology) — Publishes annually updated NSCLC guidelines incorporating both internationally approved and China-specific agents. CSCO guidelines are among the most frequently updated in the world and reflect access to domestically developed drugs.
JLCS (Japanese Lung Cancer Society) — Japanese guidelines emphasize molecular testing given the high prevalence of EGFR mutations in the Japanese population. Drug approvals in Japan are granted by the PMDA (Pharmaceuticals and Medical Devices Agency).
IASLC (International Association for the Study of Lung Cancer) — Provides the international TNM staging system (now in its 9th edition) used worldwide. Hosts the World Conference on Lung Cancer, the largest global gathering of lung cancer researchers and clinicians.
ESMO (European Society for Medical Oncology) — European clinical practice guidelines and the ESCAT molecular target classification system.

The bottom line: NSCLC treatment is a global enterprise. Advances in one region increasingly influence care in others. If you have exhausted standard US-approved options, ask your oncologist about international clinical trials and emerging agents from other regulatory systems.

Is my cancer’s molecular profile more common in certain populations? Does that affect which treatments are most studied for my subtype?
Are there clinical trials using internationally developed agents (e.g., furmonertinib for EGFR exon 20 insertions) that I might be eligible for?
If I have East-Asian ancestry, does that change the likelihood of specific driver mutations?
Are any drugs approved outside the US but not yet here that might be relevant to my situation?

Failed & De-Adopted Therapies

Knowing what has been tried and did not work is an important part of understanding where NSCLC treatment stands today. The therapies below either failed in clinical trials, were withdrawn from the market due to safety or lack of benefit, or were once standard practice but have been replaced by superior approaches. These failures are not wasted effort — each one taught researchers something about lung cancer biology and guided the development of today’s more effective treatments.

Bevacizumab (Avastin) as a Single Agent for Squamous NSCLC WITHDRAWN
Bevacizumab, an anti-VEGF antibody, was initially studied across all NSCLC histologies. In squamous cell carcinoma patients, it caused life-threatening pulmonary hemorrhage (fatal bleeding from the lungs), leading to exclusion of squamous histology from all bevacizumab NSCLC indications. It remains used only in non-squamous NSCLC, though even that role has diminished with immunotherapy advances.
Necitumumab (Portrazza) for Squamous NSCLC DE-ADOPTED
An anti-EGFR monoclonal antibody approved by the FDA in 2015 for first-line squamous NSCLC in combination with gemcitabine and cisplatin, based on the SQUIRE trial. While it showed a small survival benefit (median improvement of 1.6 months), this came with significant toxicity including skin rash, hypomagnesemia, and thromboembolic events. Due to limited clinical benefit, high cost, and the subsequent emergence of immunotherapy as the standard for squamous NSCLC, necitumumab has been largely abandoned in clinical practice. Eli Lilly withdrew it from the market in 2020.
Iniparib (BSI-201) — Supposed PARP Inhibitor FAILED
Initially promoted as a PARP inhibitor for NSCLC, iniparib was later found not to actually inhibit PARP at all. The Phase 3 trial in squamous NSCLC failed to demonstrate any improvement in overall survival or progression-free survival. This case highlighted the importance of validating a drug’s mechanism of action before launching large clinical trials.
Onartuzumab (MetMAb) — MET Antibody FAILED
A monovalent anti-MET antibody developed by Genentech for MET-positive NSCLC. The Phase 3 METLung trial was terminated early for futility after an interim analysis showed onartuzumab plus erlotinib did not improve survival compared to erlotinib alone. The failure was partly attributed to patient selection issues and the limitations of MET immunohistochemistry as a predictive biomarker. Better-designed approaches (capmatinib, tepotinib) targeting MET exon 14 skipping mutations later succeeded.
Gefitinib (Iressa) as Unselected Therapy DE-ADOPTED
The first EGFR-TKI approved for NSCLC (2003) was initially given to all NSCLC patients regardless of EGFR mutation status. The Phase 3 ISEL trial showed no overall survival benefit in unselected patients, leading the FDA to restrict its availability in 2005. It was only after the discovery that EGFR mutations predicted response that gefitinib was re-approved in 2015 — but exclusively for patients with confirmed EGFR exon 19 deletion or L858R mutations. Even then, it has since been superseded by osimertinib, which has superior efficacy and CNS penetration.
BMS-936559 (MDX-1105) — Early Anti-PD-L1 FAILED
One of the earliest anti-PD-L1 antibodies tested in solid tumors including NSCLC. While initial Phase 1 data showed some responses, Bristol-Myers Squibb chose to pursue nivolumab (anti-PD-1) instead, which showed superior activity. BMS-936559 was discontinued for NSCLC. This decision proved correct — nivolumab became a foundational immunotherapy for lung cancer.
Maintenance Docetaxel After Platinum Doublet DE-ADOPTED
Switching to maintenance docetaxel after completing first-line platinum-based chemotherapy was explored in several studies. While some trials showed modest progression-free survival benefits, the toxicity profile (neutropenia, fatigue, peripheral neuropathy) was substantial, and the overall survival advantage was marginal. With the arrival of maintenance pemetrexed and subsequently immunotherapy-based regimens, maintenance docetaxel has been largely abandoned in clinical practice.
Ipilimumab + Chemotherapy for First-Line NSCLC FAILED
Adding the anti-CTLA-4 antibody ipilimumab to first-line platinum-based chemotherapy was tested in the Phase 3 studies CA184-104 and CA184-169. Neither trial demonstrated an improvement in overall survival. Unlike in melanoma where ipilimumab transformed treatment, the CTLA-4 pathway alone was insufficient in NSCLC. Ipilimumab did find a role in NSCLC only in combination with nivolumab (anti-PD-1), not with chemotherapy alone.

Why this matters: Understanding what did not work helps you evaluate the treatments being offered to you today. It also explains why biomarker testing is so critical — drugs like gefitinib only work in the right patients, and giving them to everyone led to failure. If you encounter unproven therapies marketed online or through alternative medicine channels, ask your oncologist to help you evaluate whether they have been rigorously tested. Many have been, and many have not worked.

class="content-section" data-stage="resources">

Specialty Centers

This directory lists major centers with strong thoracic oncology programs, organized by region. Inclusion reflects program strength and national or international prominence in lung cancer care. Verify contact details when calling, as information changes.

Huntsman Cancer Institute (HCI) — University of Utah, Salt Lake City, UT
2000 Circle of Hope Drive, Salt Lake City, UT 84112
Main / new patients: 801-587-7000
NCI-designated Comprehensive Cancer Center and regional anchor for the Mountain West. Multidisciplinary thoracic oncology clinic with dedicated lung cancer tumor board, comprehensive molecular profiling (in-house NGS), extensive early-phase and cooperative group clinical trials portfolio, lung cancer screening program, HCI Wellness & Integrative Health Center. Strong programs in EGFR-mutant and ALK-positive NSCLC with access to novel agent trials.
Intermountain Health — Intermountain Medical Center — Murray, UT
5121 South Cottonwood Street, Murray, UT 84107
Cancer services: 801-507-7000
Precision Genomics program with comprehensive molecular testing and tumor board. Thoracic surgery and radiation oncology across Utah locations. Community-based clinical trial access through Intermountain’s research network. Convenient for patients along the Wasatch Front.
University of Colorado Cancer Center — Aurora, CO
720-848-0300
NCI-designated Comprehensive Cancer Center and the nearest major academic center to Utah outside Huntsman. Strong thoracic oncology program with extensive lung cancer clinical trials. Approximately 8 hours by car from Salt Lake City; remote second opinions available.

MD Anderson Cancer Center — Houston, TX
New patients: 877-632-6789
One of the largest thoracic oncology programs in the world. Deep expertise in targeted therapy, immunotherapy combinations, and surgical innovation including minimally invasive approaches. Extensive lung cancer clinical trials portfolio and structured remote second-opinion program.
Memorial Sloan Kettering Cancer Center (MSK) — New York, NY
New patients: 800-525-2225
Major thoracic surgery and medical oncology programs. Leaders in biomarker-driven therapy, liquid biopsy research, and perioperative immunotherapy trials. MSK-IMPACT comprehensive genomic profiling panel. Remote consultations available.
Mayo Clinic — Rochester, MN; Phoenix, AZ; Jacksonville, FL
Rochester: 507-538-3270 | Phoenix: 480-301-8000 | Jacksonville: 904-953-0853
All three campuses have thoracic oncology programs. Strong individualized medicine initiative with comprehensive genomic profiling. Active lung cancer clinical trials across all campuses.
Dana-Farber Cancer Institute / Brigham and Women’s Hospital — Boston, MA
New patients: 877-442-3324
Lowe Center for Thoracic Oncology with deep expertise in EGFR, ALK, and rare molecular subtypes. Active in major perioperative and targeted therapy trials. Profile comprehensive genomic panel.
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center — Baltimore, MD
410-955-8964
Pioneering work in immunotherapy for lung cancer (led early nivolumab development). Bloomberg-Kimmel Institute for Cancer Immunotherapy. Strong thoracic surgery program.
Moffitt Cancer Center — Tampa, FL
New patients: 888-663-3488
NCI-designated Comprehensive Cancer Center with a large thoracic oncology program. Leaders in lung cancer screening and immunotherapy research, including novel combination trials.
City of Hope — Duarte, CA
800-826-4673
NCI-designated Comprehensive Cancer Center with strong thoracic oncology program and active lung cancer clinical trials.

VA Salt Lake City Health Care System — George E. Wahlen VA Medical Center
500 Foothill Drive, Salt Lake City, UT 84148
801-582-1565
Thoracic oncology services with access to VA Cooperative Studies Program clinical trials. High-volume lung cancer program reflecting elevated incidence among veterans with military-related exposures (tobacco, Agent Orange, burn pit exposure, asbestos). Comprehensive molecular profiling through VA Precision Oncology Program. Veterans with lung cancer related to burn pit or toxic exposure under the PACT Act may be eligible for expanded benefits and priority care.
VA National Oncology Program
Veterans at any VA can be referred for molecular profiling through the VA National Precision Oncology Program (NPOP), which provides comprehensive genomic testing and clinical trial matching across the VA system. The VA’s lung cancer screening program (LDCT for eligible veterans) is one of the largest in the country.

Princess Margaret Cancer Centre — Toronto, ON
416-946-2000
One of the top five cancer research centers in the world. Major thoracic oncology program with comprehensive molecular profiling and extensive clinical trials. Led key lung cancer immunotherapy and targeted therapy studies.
BC Cancer — Vancouver Centre — Vancouver, BC
604-877-6000
Provincial cancer center with strong thoracic program. Known for population-based lung cancer screening research and molecular pathology expertise.
The Ottawa Hospital Cancer Centre — Ottawa, ON
613-737-7700
Active in Canadian Cancer Trials Group (CCTG) thoracic studies. Molecular profiling through Ontario Health (Cancer Care Ontario) provincial program.
McGill University Health Centre (Cedars Cancer Centre) — Montreal, QC
514-934-1934
Bilingual thoracic oncology and lung cancer screening program. Active in CCTG clinical trials.

Note: In Canada, molecular profiling is funded provincially. Access to targeted therapies may differ by province due to provincial formulary decisions. The pan-Canadian Oncology Drug Review (pCODR) process can delay access to newer agents compared to the US.

Royal Marsden Hospital — London, United Kingdom
+44 20 7352 8171
One of Europe’s largest comprehensive cancer centers. Strong thoracic oncology program, leaders in immunotherapy and biomarker-driven therapy research. Active in ESMO-endorsed clinical trials.
Gustave Roussy — Villejuif (Paris), France
+33 1 42 11 42 11
Europe’s largest cancer center. Major thoracic oncology research program. Led key immunotherapy trials including PD-L1 biomarker research.
National Cancer Center Hospital — Tokyo, Japan
Major center for EGFR-mutant NSCLC research. Led key Japanese trials with osimertinib, gefitinib, and domestically developed agents. JCOG (Japan Clinical Oncology Group) hub institution.
Samsung Medical Center — Seoul, South Korea
Leading Korean thoracic oncology program with extensive ALK and EGFR research. Active in Asia-Pacific cooperative group trials.
Peter MacCallum Cancer Centre — Melbourne, Australia
+61 3 8559 5000
Australia’s only dedicated comprehensive cancer center. Strong thoracic oncology program and active in Australasian Lung Cancer Trials Group (ALTG) studies.

Many of these centers offer international patient programs and remote second opinions. Contact their international patient offices for details on referral processes and costs.

Fertility Preservation & Pregnancy with Lung Cancer

Lung cancer in younger adults (under 50) is increasing, and many of these cases are driven by targetable gene mutations (EGFR, ALK, ROS1) rather than smoking. If you are of reproductive age, fertility preservation and pregnancy planning require careful attention because many lung cancer treatments are harmful to a developing baby.

Fertility preservation before treatment

Act before starting targeted therapy or chemotherapy — EGFR and ALK inhibitors (see below) and platinum-based chemotherapy all carry risks to eggs and sperm. Egg/embryo freezing (women) and sperm banking (men) should be arranged urgently before treatment begins. A reproductive endocrinologist can often start the process within days.
Contraception during treatment — virtually all lung cancer treatments require effective contraception for both women and their male partners during treatment and for a specified period after.

Targeted therapy and pregnancy

Osimertinib (Tagrisso) — EGFR-mutant lung cancer — causes fetal harm in animal studies. Must not be used during pregnancy. Effective contraception is required during treatment and for 6 weeks after the last dose (women) and 4 months after (men). If you are on osimertinib and become pregnant, contact your oncologist immediately.
ALK inhibitors (alectinib, brigatinib, lorlatinib) — all have animal data showing fetal harm. Effective contraception is required during treatment. Do not use during pregnancy.
Erlotinib, gefitinib, afatinib — animal studies show teratogenicity. Avoid in pregnancy.
Earlier-generation drugs — crizotinib and earlier EGFR inhibitors: same caution; avoid during pregnancy.

Immunotherapy and pregnancy

Checkpoint inhibitors (pembrolizumab, nivolumab, atezolizumab, durvalumab) are contraindicated during pregnancy. Animal studies show these drugs can cause immune-mediated damage to the placenta and fetus, leading to miscarriage or birth defects. Effective contraception is required during treatment and for several months after the last dose (varies by drug). Tell your oncologist immediately if you become pregnant while on immunotherapy.

Pregnancy after lung cancer treatment

If you have completed treatment and achieved remission or stable disease, discuss with your oncologist whether and when pregnancy might be feasible. There is no universal rule, but most experts recommend waiting 2-3 years after completing cytotoxic or targeted treatment. Genetic counseling may be relevant if your lung cancer occurred without a smoking history or at a young age.

Key message: Most lung cancer medications are harmful to a developing baby. Use effective contraception during treatment, preserve fertility before starting treatment, and discuss any pregnancy plans openly with your oncologist.

Glossary

Key terms used throughout this guide. Click to expand.

NSCLC (non-small cell lung cancer) — The most common form of lung cancer (~85% of cases), encompassing adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. Distinguished from small cell lung cancer (SCLC), which is treated differently.
Adenocarcinoma — The most common NSCLC subtype (~40%), arising from glandular cells, often in the outer lung. Most likely to harbor targetable driver mutations.
Squamous cell carcinoma — NSCLC subtype (~25–30%) strongly linked to smoking, arising in central airways. Less likely to have targetable mutations; often responds well to immunotherapy.
Large cell carcinoma — Less common NSCLC subtype (~5–10%) that can arise anywhere in the lung. Increasingly classified by molecular features.

EGFR (epidermal growth factor receptor) — A protein on cell surfaces that, when mutated, drives cancer growth. The most common actionable mutation in NSCLC adenocarcinoma. Treated with TKIs such as osimertinib.
ALK (anaplastic lymphoma kinase) — A gene rearrangement found in ~5% of NSCLC, most common in younger never-smokers. Treated with ALK inhibitors (alectinib, lorlatinib, brigatinib).
ROS1 — A gene rearrangement found in ~1–2% of NSCLC. Similar biology to ALK. Treated with crizotinib, entrectinib, or repotrectinib.
KRAS G12C — A specific KRAS mutation found in ~13% of NSCLC adenocarcinomas, more common in smokers. Treated with sotorasib or adagrasib.
MET exon 14 (skipping mutation) — Found in ~3–4% of NSCLC. Treated with capmatinib or tepotinib (US) or savolitinib (China).
RET (rearranged during transfection) — A gene fusion found in ~1–2% of NSCLC. Treated with selpercatinib or pralsetinib.
NTRK (neurotrophic tyrosine receptor kinase) — Rare gene fusions (<1% of NSCLC) treatable with larotrectinib or entrectinib. Found across many cancer types.
HER2 (human epidermal growth factor receptor 2) — Mutations found in ~2–3% of NSCLC. Treated with trastuzumab deruxtecan (T-DXd), an antibody-drug conjugate.
PD-L1 TPS (programmed death-ligand 1, tumor proportion score) — A measure of how much PD-L1 protein is expressed on tumor cells. Higher PD-L1 (≥50%) predicts better response to immunotherapy alone; lower levels may still benefit from immunotherapy plus chemotherapy.

NGS (next-generation sequencing) — A comprehensive molecular test that analyzes many genes simultaneously from a single tissue or blood sample. The preferred method for identifying all actionable mutations at once, rather than testing one gene at a time.
Liquid biopsy — A blood test that detects tumor DNA circulating in the bloodstream (ctDNA). Used when tissue biopsy is insufficient, to monitor treatment response, or to detect resistance mutations. Faster results than tissue biopsy but may miss some mutations.

Neoadjuvant therapy — Treatment given before surgery to shrink the tumor and improve surgical outcomes. In NSCLC, neoadjuvant immunotherapy plus chemotherapy is a new standard for resectable disease.
Adjuvant therapy — Treatment given after surgery to kill remaining cancer cells and reduce the risk of recurrence. May include chemotherapy, targeted therapy (e.g., osimertinib for EGFR-positive), or immunotherapy.
Perioperative therapy — The combination of neoadjuvant and adjuvant treatment — therapy both before and after surgery. An increasingly common approach in NSCLC based on recent trials.
Immunotherapy — Treatment that helps the body’s own immune system recognize and attack cancer cells. In NSCLC, this primarily means immune checkpoint inhibitors (anti-PD-1/PD-L1 antibodies) such as pembrolizumab, nivolumab, atezolizumab, and durvalumab.
TKI (tyrosine kinase inhibitor) — An oral targeted therapy that blocks specific proteins driving cancer growth. Examples include osimertinib (EGFR), alectinib (ALK), and sotorasib (KRAS G12C). Usually taken as daily pills at home.
ADC (antibody-drug conjugate) — A targeted therapy that combines an antibody (which finds cancer cells) with a chemotherapy payload (which kills them). Delivers chemotherapy directly to the tumor, reducing damage to healthy tissue. Examples: trastuzumab deruxtecan (HER2), datopotamab deruxtecan (TROP2).